Rebecca D. Chernock

Rebecca D. Chernock

Auto-generated profile, based on publicly available information

Rebecca D. Chernock

Department of Pathology, Washington University School of Medicine, St. Louis, Missouri

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2010 in American Journal of Surgical Pathology
Verified
Journal Article
Closed access
JLJames S. Jr Lewis
James S. Jr Lewis
WTWade L. Thorstad
Wade L. Thorstad
RCRebecca D. Chernock
Rebecca D. Chernock
BHBruce H. MB Haughey
Bruce H. MB Haughey
JYJames H. Yip
James H. Yip
SESamir K. Dmd El-Mofty
Samir K. Dmd El-Mofty
Background In the human papillomavirus (HPV) era, the best way to assess oropharyngeal squamous carcinomas (SCC) for risk stratification is not clear. Many recommend use of both p16 immunohistochemistry and HPV in situ hybridization (ISH). A significant minority of tumors are p16 positive and HPV ISH negative, the significance of which is unclear. Methods Two hundred thirty-nine oropharyngeal SCC were tested by immunohistochemistry for p16 and by ISH for high-risk HPV. For p16 positive, HPV ISH negative cases, PCR was conducted for HPV. The findings were correlated with pathologic and clinical findings. Results Of the 239 cases, 187 (78%) were positive for p16. Of these, 139 (74%) were positive for HPV by ISH. Of the remaining 48 cases, 45 had material for PCR. Nineteen were positive for HPV, leaving a group of 26 p16 positive and HPV undetectable SCCs. In the p16 positive cohort, there was no difference in survival between HPV ISH positive and negative cases. Comparing the HPV ISH positive and HPV ISH and PCR negative SCC, there was again no difference in survival. p16 positive, HPV negative SCC still had significantly better survival than p16 negative SCC in univariate and multivariate analysis. Conclusions Outcomes for p16 positive, HPV negative oropharyngeal SCC are not significantly different from p16 positive, HPV positive tumors and are significantly better than for p16 negative tumors. These results suggest that p16 immunohistochemistry alone is the best test to use for risk stratification in oropharyngeal SCC.

11 July 2009 in Head and Neck Pathology
Verified
Journal Article
Open access
PDF file
RCRebecca D. Chernock
Rebecca D. Chernock
SESamir K. El-Mofty
Samir K. El-Mofty
WTWade L. Thorstad
Wade L. Thorstad
CPCurtis A. Parvin
Curtis A. Parvin
JLJames S. Lewis
James S. Lewis
Human papilloma virus (HPV) is an etiologic agent in a subset of oropharyngeal squamous cell carcinomas (SCCs). The aim of this study was to sub-classify SCC of the oropharynx based upon histologic features into nonkeratinizing (NK) SCC, keratinizing (K) SCC, and hybrid SCC, and determine the frequency of HPV and patient survival in each group. Patients with oropharyngeal SCC with a minimum of 2 years of clinical follow-up were identified from radiation oncology databases from 1997 to 2004. All patients received either up front surgery with postoperative radiation or definitive radiation based therapy. In situ hybridization (ISH) for high-risk HPV subtypes and immunohistochemistry for p16, a protein frequently up-regulated in HPV-associated carcinomas, were performed. Overall and disease-specific survival were assessed. Of 118 cases, 46.6% were NK SCC, 24.6% K SCC and 28.8% hybrid SCC. NK SCC occurred in slightly younger patients that were more often male. It more frequently presented with lymph node metastases and was surgically resected compared to K SCC. NK SCC was significantly more likely to be HPV and p16 positive than KSCC (P < 0.001) and to have better overall and disease-specific survival (P = 0.0002; P = 0.0142, respectively). Hybrid SCC was also more likely than K SCC to be HPV and p16 positive (P = 0.003; P = 0.002, respectively) and to have better overall survival (P = 0.0105). Sub-classification of oropharyngeal SCC by histologic type provides useful clinical information. NK SCC histology strongly predicts HPV-association and better patient survival compared to K SCC. Hybrid SCC appears to have an intermediate frequency of HPV-association and patient survival.

14 January 2020 in Laboratory Investigation
Verified
Journal Article
Closed access
PDF file
RCRebecca D. Chernock
Rebecca D. Chernock
BRBarbara Rivera
Barbara Rivera
NBNicla Borrelli
Nicla Borrelli
DHD. Ashley Hill
D. Ashley Hill
SFSomayyeh Fahiminiya
Somayyeh Fahiminiya
YNYuri E. Nikiforov
Yuri E. Nikiforov

3 April 2023 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
Sidharth PuramSidharth Puram
Sidharth Puram
MMMichael Mints
Michael Mints
APAnanya Pal
Ananya Pal
ZQZongtai Qi
Zongtai Qi
ARAshley Reeb
Ashley Reeb
ITItay Tirosh
Itay Tirosh

29 September 2023 in Science Immunology
Verified
Journal Article
Closed access
GOGiacomo Oliveira
Giacomo Oliveira
AEAnn Marie Egloff
Ann Marie Egloff
AAAlexander B. Afeyan
Alexander B. Afeyan
JWJacquelyn O. Wolff
Jacquelyn O. Wolff
ZZZexiang Zeng
Zexiang Zeng
RURavindra Uppaluri
Ravindra Uppaluri
About 50% of patients with locally advanced head and neck squamous cell carcinoma (HNSCC) experience recurrences after definitive therapy. The presurgical administration of anti–programmed cell death protein 1 (PD-1) immunotherapy results in substantial pathologic tumor responses (pTR) within the tumor microenvironment (TME). However, the mechanisms underlying the dynamics of antitumor T cells upon neoadjuvant PD-1 blockade remain unresolved, and approaches to increase pathologic responses are lacking. In a phase 2 trial (NCT02296684), we observed that 45% of patients treated with two doses of neoadjuvant pembrolizumab experienced marked pTRs (≥50%). Single-cell analysis of 17,158 CD8 + T cells from 14 tumor biopsies, including 6 matched pre-post neoadjuvant treatment, revealed that responding tumors had clonally expanded putative tumor-specific exhausted CD8 + tumor-infiltrating lymphocytes (TILs) with a tissue-resident memory program, characterized by high cytotoxic potential (CTX + ) and ZNF683 expression, within the baseline TME. Pathologic responses after 5 weeks of PD-1 blockade were consistent with activation of preexisting CTX + ZNF683 + CD8 + TILs, paralleling loss of viable tumor and associated tumor antigens. Response was associated with high numbers of CD103 + PD-1 + CD8 + T cells infiltrating pretreatment lesions, whereas revival of nonexhausted persisting clones and clonal replacement were modest. By contrast, nonresponder baseline TME exhibited a relative absence of ZNF683 + CTX + TILs and subsequent accumulation of highly exhausted clones. In HNSCC, revival of preexisting ZNF683 + CTX + TILs is a major mechanism of response in the immediate postneoadjuvant setting.